A single shot that lasts: researchers test Long-Acting drug in healthy volunteers
NCT ID NCT07093580
First seen Oct 06, 2026 · Last updated Oct 16, 2026 · Updated 2 times
Summary
Researchers are testing an experimental long-acting injectable drug called S-892216-LAI in healthy adults. The trial measures how safe and tolerable the drug is, and how the body absorbs and clears it after one or more doses. Participants receive either the drug or a saline placebo. The goal is to understand the drug's basic behavior in the body before it is tested in patients.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- S-892216-LAI, an experimental long-acting injectable drug
- What this could lead to
- If it works, this could lead to a long-acting injectable form of S-892216 that needs fewer doses than daily pills.
- What could go wrong
- This is a first-in-human Phase 1 trial with 98 healthy volunteers, so researchers are mainly checking safety and blood levels, not whether the drug treats any disease. Many drugs fail at this stage.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1
The first testing in people. Mainly checks safety and dose, usually in a small group.
- Participants
-
About 128 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jul 2025
- Expected to finish
-
Jun 2028
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 55 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Key Inclusion Criteria: * Body mass index (BMI) ≥18.5 and ≤32.0 kilograms (kg)/square meter (m\^2) Key Exclusion Criteria: * Presence or history of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrinological, hematological, neurological, or ophthalmological (for example, increased intra-ocular pressure) disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study intervention; or interfering with the interpretation of data per the investigator's assessment. * History of cancer except for basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of metastatic disease for 3 years. * Require medication or other treatment (for example, dietary restrictions or physical therapy). * Participated in any other clinical study involving an investigational study intervention or any other type of medical research within 30 days, or 5 times the half-life of the investigational drug, before signing of the informed consent form (ICF) for this study or who are currently participating in such a study. * Positive test results of the following at screening or within 6 months prior to administration of study intervention: hepatitis B surface antigen (HBsAg); hepatitis C virus antibody (HCV); and human immunodeficiency virus (HIV) antigen/antibody. * Positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) reverse transcription polymerase chain reaction (RT-PCR) test result, positive transcription-mediated amplification test result, positive antigen test result, or any other test approved according to local regulations at check in for each period on admission. * Known allergy/sensitivity or any hypersensitivity to components of S-892216-LAI or placebo for S-892216-LAI. * Used cannabis (medical or recreational), tobacco, or nicotine-containing products (including e-cigarettes, pipe tobacco, cigar, chewing tobacco, nicotine patch, and nicotine gum) within 6 months prior to admission. Note: Other protocol-defined inclusion/exclusion criteria may apply.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Healthy participants are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Altasciences
RECRUITINGCypress, California, 90630, United States
-
ICON Clinical Research: Lenexa
ACTIVE_NOT_RECRUITINGLenexa, Kansas, 66219, United States
-
ICON Clinical Research: Salt Lake City
ACTIVE_NOT_RECRUITINGSalt Lake City, Utah, 84124, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can one experimental drug rewire how the body handles four common medicines?
- Clemizole gets a closer look: can an old drug be retooled?
- Pfizer tests two ways to deliver experimental weight drug
- Kidney trouble and cancer drugs: scientists map how the body handles velzatinib
- Does the speed of a clotting drug change blood pressure during C-Section?
- Stomach acid drugs and velzatinib: scientists test whether they clash